Sagent Pharmaceuticals, Inc. (SGNT) Reports Q2 EPS Loss of $0.37, Revenues Grow 205%
Tweet Send to a FriendGet Alerts SGNT Hot Sheet
Trade SGNT Now!
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of ($0.37), $0.16 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $32.3 million versus the consensus estimate of $34.53 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- NetApp (NTAP) Tops Q4 EPS by 1c; Boosts Buyback, Plans Job Cuts, Initiates Dividend
- Monro Muffler, Inc. (MNRO) Reports In-Line Q4 EPS; Guides Q1, FY14
- TJX Cos. (TJX) Reports In-Line Q1 EPS; Guides Q2 EPS, Narrows FY14 Outlook
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
